Literature DB >> 29392710

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.

Elizabeth J Phillips1, Chonlaphat Sukasem2,3, Michelle Whirl-Carrillo4, Daniel J Müller5,6, Henry M Dunnenberger7, Wasun Chantratita8,9, Barry Goldspiel10, Yuan-Tsong Chen11,12, Bruce C Carleton13, Alfred L George14, Taisei Mushiroda15, Teri Klein4, Roseann S Gammal16,17, Munir Pirmohamed18.   

Abstract

The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.
© 2018 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29392710      PMCID： PMC5847474          DOI： 10.1002/cpt.1004

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  40 in total

1.  HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.

Authors:  Nahoko Kaniwa; Yoshiro Saito; Michiko Aihara; Kayoko Matsunaga; Masahiro Tohkin; Kouichi Kurose; Hirokazu Furuya; Yukitoshi Takahashi; Masaaki Muramatsu; Shigeru Kinoshita; Masamichi Abe; Hiroko Ikeda; Mariko Kashiwagi; Yixuan Song; Mayumi Ueta; Chie Sotozono; Zenro Ikezawa; Ryuichi Hasegawa
Journal:  Epilepsia       Date:  2010-11-03       Impact factor: 5.864

2.  HLA-A*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population.

Authors:  Byung-Keun Kim; Jae-Woo Jung; Tae-Bum Kim; Yoon-Seok Chang; Hae-Sim Park; Jangsup Moon; Soon-Tae Lee; Keun-Hwa Jung; Ki-Young Jung; Kon Chu; Sang Kun Lee; Hye-Ryun Kang; Heung-Woo Park
Journal:  Ann Allergy Asthma Immunol       Date:  2017-03-25       Impact factor: 6.347

3.  PharmGKB summary: carbamazepine pathway.

Authors:  Caroline F Thorn; Susan G Leckband; John Kelsoe; J Steven Leeder; Daniel J Müller; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-12       Impact factor: 2.089

4.  Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans.

Authors:  Sae-Hoon Kim; Kyung Wha Lee; Woo-Jung Song; Sang-Heon Kim; Young-Koo Jee; Sang-Min Lee; Hye-Ryun Kang; Heung-Woo Park; Sang-Heon Cho; Seong-Ho Park; Kyung-Up Min; Yoon-Seok Chang
Journal:  Epilepsy Res       Date:  2011-09-13       Impact factor: 3.045

5.  Drug hypersensitivity: pharmacogenetics and clinical syndromes.

Authors:  Elizabeth J Phillips; Wen-Hung Chung; Maja Mockenhaupt; Jean-Claude Roujeau; Simon A Mallal
Journal:  J Allergy Clin Immunol       Date:  2011-03       Impact factor: 10.793

6.  Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?

Authors:  I Garcia-Doval; L LeCleach; H Bocquet; X L Otero; J C Roujeau
Journal:  Arch Dermatol       Date:  2000-03

7.  Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.

Authors:  Amal Nassif; Armand Bensussan; Laurence Boumsell; Aurelien Deniaud; Homayoun Moslehi; Pierre Wolkenstein; Martine Bagot; Jean-Claude Roujeau
Journal:  J Allergy Clin Immunol       Date:  2004-11       Impact factor: 10.793

8.  Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population.

Authors:  Choong-Chor Chang; Chun-Lai Too; Shahnaz Murad; Suraiya Hani Hussein
Journal:  Int J Dermatol       Date:  2011-02       Impact factor: 2.736

9.  Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

Authors:  K E Caudle; A E Rettie; M Whirl-Carrillo; L H Smith; S Mintzer; M T M Lee; T E Klein; J T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2014-08-06       Impact factor: 6.875

Review 10.  HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review.

Authors:  V L Yip; A G Marson; A L Jorgensen; M Pirmohamed; A Alfirevic
Journal:  Clin Pharmacol Ther       Date:  2012-11-07       Impact factor: 6.875
View more
  51 in total

Review 1.  Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.

Authors:  Ramon Cacabelos
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

Review 2.  Controversies in drug allergy: Testing for delayed reactions.

Authors:  Elizabeth J Phillips; Paul Bigliardi; Andreas J Bircher; Ana Broyles; Yoon-Seok Chang; Wen-Hung Chung; Rannakoe Lehloenya; Maja Mockenhaupt; Jonny Peter; Munir Pirmohamed; Jean-Claude Roujeau; Neil H Shear; Luciana Kase Tanno; Jason Trubiano; Rocco Valluzzi; Annick Barbaud
Journal:  J Allergy Clin Immunol       Date:  2018-12-17       Impact factor: 10.793

3.  The 10th International Congress on Cutaneous Adverse Drug Reactions, Shimane, Japan, 2018: Focus on New Discoveries.

Authors:  Cristina Olteanu; Neil H Shear; Eishin Morita; Wen-Hung Chung; Hiroyuki Niihara; Setsuko Matsukura; Rena Hashimoto; Roni P Dodiuk-Gad
Journal:  Drug Saf       Date:  2019-06       Impact factor: 5.606

Review 4.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

5.  Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine.

Authors:  William V Bobo; Patricio Riva-Posse; Fernando S Goes; Sagar V Parikh
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

6.  Slow graded reintroduction of oxcarbazepine for delayed maculopapular eruption.

Authors:  Christine R F Rukasin; Elizabeth J Phillips; Allison E Norton
Journal:  Ann Allergy Asthma Immunol       Date:  2019-06-12       Impact factor: 6.347

7.  High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms.

Authors:  Andrew A Somogyi; Daniel T Barratt; Elizabeth J Phillips; Kylies Moore; Fahmida Ilyas; Genevieve M Gabb
Journal:  Br J Clin Pharmacol       Date:  2019-07-19       Impact factor: 4.335

8.  Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine.

Authors:  Susan R Snyder; Jing Hao; Larisa H Cavallari; Zhi Geng; Amanda Elsey; Julie A Johnson; Zahurin Mohamed; Nathorn Chaiyakunapruk; Huey Yi Chong; Maznah Dahlui; Fatiha H Shabaruddin; George P Patrinos; Christina Mitropoulou; Marc S Williams
Journal:  Public Health Genomics       Date:  2019-06-12       Impact factor: 2.000

Review 9.  Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada.

Authors:  Abdullah Al Maruf; Mikayla Fan; Paul D Arnold; Daniel J Müller; Katherine J Aitchison; Chad A Bousman
Journal:  Can J Psychiatry       Date:  2020-02-17       Impact factor: 4.356

Review 10.  The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later.

Authors:  Mary V Relling; Teri E Klein; Roseann S Gammal; Michelle Whirl-Carrillo; James M Hoffman; Kelly E Caudle
Journal:  Clin Pharmacol Ther       Date:  2019-11-05       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.